Pipeline

We investigate fundamental biology through an academic lens and with a business mindset

Immune and COVID-19 rejuvenation, HIV (Roman Regimen)

Completing IMPD stage (Q1 2023). First in Human dosing planned in late 2023 (Influenza vaccination of the elderly)

Oncology

Pre-clinical studies in both stand alone protocols and in combination with check point inhibitors

Lifespan extension, Mitochondrial diseases

Drug discovery, Lead optimisation 2022

Alzheimer’s disease

Drug discovery, target validation 2022

Neurodegenerative disorders E.g.: Schizophrenia

Drug discovery, target validation 2022.

Autoimmune disorders

Drug discovery, lead optimisation. ®*, pending

We develop first-in class compounds to achieve human rejuvenation.